Clinical efficacy and safety of platinum-containing neoadjuvant immunotherapy for triple-negative breast cancer

Objective To evaluate the clinical efficacy and safety of platinum-containing neoadjuvant immunotherapy for triple-negative breast cancer. Methods Sixty-four patients with PD-L1 positive triple-negative breast cancer were enrolled and randomly divided into the control（n = 32）and observation groups（n = 32）. In the control group，preoperative chemotherapy regimen of albumin-bound paclitaxel plus cisplatin（TP）was given，while the observation group received platinum-containing neoadjuvant immunotherapy--combined with programmed death receptor-1（PD-1）inhibitor carrilizumab on the basis of TP chemotherapy regimen of control group. At 4 weeks post-neoadjuvant chemotherapy，whether modified radical surgery or breast-conserving surgery was chosen based on surgical indications，and whether axillary lymph node dissection was performed according to intraoperative sentinel lymph node biopsy results. The objective response rate，disease control rate，pathological complete response rate，breast conservation rate，axillary lymph nod